Trial Profile
GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Guadecitabine (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Mar 2023 Results assessing safety and efficacy of guadecitabine plus atezolizumab in metastatic urothelial carcinoma, published in the Clinical Cancer Research.
- 10 Apr 2021 Primary endpoint of Objective Response Rate has not been met according to results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 10 Apr 2021 Status changed from active, no longer recruiting to discontinued as per it was determined that the trial would not meet its primary endpoint and it closed early according to results presented at the 112th Annual Meeting of the American Association for Cancer Research